Three months ended

March 31, 

June 30, 

September 30, 

December 31, 

2017

2017

2017

2017(1)

Revenues

$

1,932

$

2,054

$

2,169

$

2,203

Gross profit

392

437

474

509

Restructuring, impairment and plant closing costs

 9

 3

 1

 7

Income from continuing operations

99

138

116

230

Net income

92

183

179

287

Net income attributable to noncontrolling interests(2)

16

16

32

41

Net income attributable to Huntsman Corporation

76

167

147

246

Basic income per share(3):

Income from continuing operations attributable to Huntsman Corporation common stockholders

0.35

0.51

0.36

0.79

Net income attributable to Huntsman Corporation common stockholders

0.32

0.70

0.62

1.03

Diluted income per share(3):

Income from continuing operations attributable to Huntsman Corporation common stockholders

0.34

0.50

0.34

0.77

Net income attributable to Huntsman Corporation common stockholders

0.31

0.69

0.60

1.00

Three months ended

March 31, 

June 30, 

September 30, 

December 31, 

2016

2016

2016

2016(4)

Revenues

$

1,815

$

1,968

$

1,831

$

1,904

Gross profit

390

424

356

356

Restructuring, impairment and plant closing costs (credits)

 2

16

38

(9)

Income from continuing operations

85

107

40

133

Net income

62

94

64

137

Net income attributable to noncontrolling interests(2)

 6

 7

 9

 9

Net income attributable to Huntsman Corporation

56

87

55

128

Basic income per share(3):

Income from continuing operations attributable to Huntsman Corporation common stockholders

0.33

0.42

0.13

0.52

Net income attributable to Huntsman Corporation common stockholders

0.24

0.37

0.23

0.54

Diluted income per share(3):

Income from continuing operations attributable to Huntsman Corporation common stockholders

0.33

0.42

0.13

0.51

Net income attributable to Huntsman Corporation common stockholders

0.24

0.36

0.23

0.53

Three months ended

March 31, 

June 30, 

September 30, 

December 31, 

2017

2017

2017

2017(1)

Revenues

$

1,932

$

2,054

$

2,169

$

2,203

Gross profit

393

438

475

509

Restructuring, impairment and plant closing costs

 9

 3

 1

 7

Income from continuing operations

98

139

115

227

Net income

91

182

177

284

Net income attributable to noncontrolling interests(2)

16

16

32

41

Net income attributable to Huntsman International

75

166

145

243

Three months ended

March 31, 

June 30, 

September 30, 

December 31, 

2016

2016

2016

2016(4)

Revenues

$

1,815

$

1,968

$

1,831

$

1,904

Gross profit

391

425

357

357

Restructuring, impairment and plant closing costs (credits)

 2

16

38

(9)

Income from continuing operations

85

109

41

132

Net income

62

93

63

136

Net income attributable to noncontrolling interests(2)

 6

 7

 9

 9

Net income attributable to Huntsman International

56

86

54

127

(1)

On December 22, 2017, the U.S. enacted the U.S. Tax Reform Act. During the fourth quarter of 2017, we and Huntsman International recorded the impact of the U.S. Tax Reform Act which resulted in a net $52 million and $53 million, respectively, income tax benefit.

(2)

In connection with the Venator IPO in August 2017, we separated the P&A Business and, beginning in the third quarter of 2017, we reported the results of operations of the P&A Business as discontinued operations in our consolidated financial statements for all periods presented. See “Note 3. Discontinued Operations and Business Dispositions—Separation of P&A Business.”

(3)

Basic and diluted income per share are computed independently for each of the quarters presented based on the weighted average number of common shares outstanding during that period. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted earnings per share.

(4)

On December 30, 2016, our Performance Products segment completed the sale of its European surfactants business to Innospec Inc. for $199 million in cash plus our retention of trade receivables and payables for an enterprise value of $225 million. For further information, see “Note 3. Discontinued Operations and Business Dispositions—Sale of European Surfactants Manufacturing Facilities.”